expert perspectives

Expert Perspectives in Relapsed/Refractory Diffuse Large B-Cell Lymphoma to Cover Key Topics in R/R DLBCL Treatment

Overview

Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. This issue of Expert Perspectives in Relapsed/Refractory Diffuse Large B-Cell Lymphoma will feature selected topics in R/R DLBCL that we hope you will find of value in your clinical practice.

The clinicians who were surveyed selected the following experts and topics.

Community-Selected Experts: 

Jeremy S. Abramson, MD, MMSc

Director, Jon and JoAnn Hagler Center for Lymphoma
Jon and JoAnn Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Brad Kahl, MD

Professor of Medicine, Division of Oncology
Washington University School of Medicine
Director, Lymphoma Program
Alvin J. Siteman Cancer Center
Saint Louis, MO

Matthew J. Matasar, MD

Associate Member, Lymphoma Service
Section Head, Aggressive B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
New York, NY


Community-Selected Topics: 

Expert Roundtables 

    Therapeutic Sequencing in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Investigational and Emerging Therapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Improving Outcomes for Patients With High-Risk Diffuse Large B-Cell Lymphoma
    Curative Intent in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Different Paths and Different Strategies

Clinical Topic Updates 

    Predictive Biomarkers for Chimeric Antigen Receptor T-Cell Therapy
    Novel Agents as Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Double Hit, Triple Hit, and Cell of Origin in Diffuse Large B-Cell Lymphoma
    CD19-Directed Therapies and Antibody-Drug Conjugates for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Patient Care Perspectives 

    "Off-the-Shelf" Treatment Options in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Safety and Tolerability of Salvage Therapy and Later-Line Treatments in Diffuse Large B-Cell Lymphoma
    Options for Patients Who Do Not Proceed to Autologous Stem Cell Transplantation or Chimeric Antigen Receptor T-Cell Therapy
    Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Assessing the Patient’s Treatment Goals

More in R R DLBCL

Thumb

R R DLBCL

CD19-Directed Therapies and Antibody-Drug Conjugates for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical Topic Updates by Brad Kahl, MD

Several CD19-directed therapies have been approved by the US Food and Drug Administration (FDA) for the treatment of relapsed/refractory diffuse la...READ MORE

Thumb

R R DLBCL

“Off-the-Shelf” Treatment Options in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Patient Care Perspectives by Brad Kahl, MD

Patients with relapsed diffuse large B-cell lymphoma (DLBCL) are often highly symptomatic and need immediate relief with “off-the-shelf” therapies ...READ MORE

Thumb

R R DLBCL

Bridging Therapy vs Debulking Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical Topic Updates by Matthew J. Matasar, MD

Our featured expert comments on bridging therapy, debulking therapy, and chimeric antigen receptor (CAR) T-cell therapy eligibility in the treatmen...READ MORE

More In Oncology

cGVHD

Chronic Graft-versus-Host Disease: Biomarkers, Mediators, and Druggable Targets

Clinical Topic Updates by David Miklos, MD, PhD

cGVHD

Evolving Transplant Technology and Chronic Graft-versus-Host Disease

Patient Care Perspectives by Edmund K. Waller, MD, PhD, FACP

cGVHD

Advancements in the Management of Chronic Graft-versus-Host Disease

Expert Roundtables by Corey Cutler, MD, MPH, FRCPC; David Miklos, MD, PhD; and Edmund K. Waller, MD, PhD, FACP